|
JOBS | TENDERS | DATING |
|
|
THE SMART NEWS SOURCE | Feb 11 2012 02:54 | LAST UPDATED Feb 11 2012 02:54 |
|
The high cost of drugs needed to treat Aids patients is putting the lives of thousands at risk, medical humanitarian organisation Médecins sans Frontières (MSF) said on Monday. "Patients needing new drug regimens will return to Aids death row," it warned in a statement released at the 2009 International Aids Society conference in Cape Town. MSF called on drug companies to submit their Aids drug patents to a "patent pool", set up by international drug financing agency Unitaid, and so allow poor countries to access critically needed drugs at affordable prices. It said figures from a long-running public-sector Aids treatment programme in Khayelitsha showed 16% of patients receiving antiretroviral treatment experienced failure on their first-line drug regimen within five years. "A quarter of those patients who were switched to a second-line regimen failed on this alternative treatment line within two years. As no third-line regimen is available in South Africa, like in many other developing countries, these patients are now at risk of dying." Unlike older first-line drugs, most second- and third-line drugs were patented and priced out of reach for patients in developing countries. "In some of these countries, switching from a first- to second-line regimen increases treatment costs as much as seventeen-fold. "To stop spiralling costs, countries will have to routinely use measures such as compulsory licences, which allow the generic manufacture of drugs under patent to ensure affordable treatments." MSF said the patent pool would provide generic producers or researchers with drug licences in exchange for a fee paid to the originator company. -- Sapa  CONTINUES BELOW TOPICS IN THIS ARTICLE
comment guidelines
|
Client Media Releases
IN THIS WEEK'S PAPER
SUBSCRIBE: - Paper edition - iPad edition (NEW!) - Kindle edition - Digital edition Read stories online  @mailandguardian - Top stories & newsflashes @NicDawes - M&G editor Nic Dawes @ChrisRoperZA - Editor, M&G Online @amabhungane - M&G Centre for Investigative Journ @mgfeed - Our whole news feed Advertisements |
Contact Us | About Us | Story Tip-offs | Social media policy | Online Advertising | Print Advertising | Subscriptions | Topics A-Z | Mobile Sites | Privacy Policy | RSS Feed
All material © Mail & Guardian Online. Material may not be published or reproduced in any form without prior written permission.
 |
 |